

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56)

RRID:AB_2889063

Type: Antibody

Proper Citation

BioLegend Cat# 348805, RRID:AB_2889063

Antibody Information

URL: http://antibodyregistry.org/AB_2889063

Proper Citation: BioLegend Cat# 348805, RRID:AB_2889063

Target Antigen: CD3, CD14, CD16, CD19, CD20, CD56

Host Organism: mouse

Clonality: cocktail

Comments: Discontinued: 2021; Applications: FC

Antibody Name: Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56)

Description: This cocktail targets CD3, CD14, CD16, CD19, CD20, CD56

Target Organism: human

Clone ID: UCHT1, HCD14, 3G8, HIB19, 2H7, HCD56,

Antibody ID: AB_2889063

Vendor: BioLegend

Catalog Number: 348805

Record Creation Time: 20231110T031709+0000

Record Last Update: 20260829T211614+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56).

Warning: Discontinued: 2021
Discontinued: 2021; Applications: FC

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fukasawa K, et al. (2026) Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis. *iScience*, 29(1), 114533.

Mosialou I, et al. (2025) A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. *Cancer cell*, 43(6), 1007.

Kobelski MM, et al. (2024) Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies. *Endocrinology*, 165(12).

Wu Z, et al. (2023) Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. *Cell reports. Medicine*, 4(8), 101160.

Wang X, et al. (2021) Dysregulated hematopoiesis in bone marrow marks severe COVID-19. *Cell discovery*, 7(1), 60.